Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML0346

Sigma-Aldrich

Alosetron hydrochloride

≥98% (HPLC)

Synonyme(s) :

2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H18N4O·HCl
Numéro CAS:
122852-69-1
Poids moléculaire :
330.81
Numéro MDL:
MFCD09028027
Code UNSPSC :
12352200
ID de substance PubChem :
329825350
Nomenclature NACRES :
NA.77

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

white to beige

Solubilité

H2O: ≥5 mg/mL at warmed

Température de stockage

2-8°C

Chaîne SMILES 

CN1C2=C(C=CC=C2)C3=C1CCN(CC4=C(C)N=CN4)C3=O.Cl

InChI

1S/C17H18N4O.ClH/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2;/h3-6,10H,7-9H2,1-2H3,(H,18,19);1H

Clé InChI

FNYQZOVOVDSGJH-UHFFFAOYSA-N

Informations sur le gène

human ... HTR3A(3359)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Actions biochimiques/physiologiques

Alosetron is a potent and highly selective antagonist of serotonin 5-HT3 receptors, nonselective cation channels found predominantly in the enteric nervous system of the gastrointestinal tract. These receptors are involved in the regulation of visceral pain, colonic transit and GI secretions that can contribute to the pathophysiology of irritable bowel syndrome (IBS). Alosetron is used clinically for treatment of women with severe diarrhea-predominant IBS.

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301,H319,H412

Classification des risques

Acute Tox. 3 Oral - Aquatic Chronic 3 - Eye Irrit. 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Eric Shah et al.
The American journal of medicine, 125(4), 381-393 (2012-03-27)
Current treatment options for irritable bowel syndrome are limited and often poorly studied. A select few drugs have been studied in irritable bowel syndrome, and the number needed to treat is frequently used to assess the relative efficacy of these
James H Lewis
Drug safety, 34(7), 545-565 (2011-06-15)
Ischaemic colitis (IC) is the most common form of ischaemic injury to the gastrointestinal (GI) tract. IC typically presents with the sudden onset of lower abdominal pain, cramping and rectal bleeding, and is usually self-limited with low morbidity, although it
Andrea Fantuzzi et al.
Analytical chemistry, 82(24), 10222-10227 (2010-11-26)
This paper is the first report of a P450-electrode in a microfluidic format. A 30 μL microfluidic cell was made in poly(methyl methacrylate) containing the inlet, outlet, and reaction chamber with two electrode strips, one of which contains the human
Lin Chang et al.
The American journal of gastroenterology, 105(4), 866-875 (2010-03-04)
Alosetron is a potent, selective 5-HT(3) receptor antagonist prescribed for women with severe diarrhea-predominant irritable bowel syndrome (IBS-D) under a risk management plan (RMP). The RMP was implemented following cases of ischemic colitis (IC) and complications of constipation (CoC) associated
Larry D Lynd et al.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 13(4), 411-417 (2009-09-12)
There is consensus that a more transparent, explicit, and rigorous approach to benefit-risk evaluation is required. The objective of this study is to evaluate the incremental net benefit (INB) framework for undertaking quantitative benefit-risk assessment by performing a quantitative benefit-risk
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique